Loading…
Daré Bioscience, Inc. is projected to rise to $2.08 by 2027, a +3% move from its current price of $2.02. DARE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.96 | $2.02 | $2.09 | +0.01% |
| Jul 15 | $1.93 | $2.02 | $2.11 | +0.02% |
| Jul 16 | $1.91 | $2.02 | $2.13 | +0.03% |
| Jul 17 | $1.90 | $2.02 | $2.15 | +0.05% |
| Jul 18 | $1.88 | $2.02 | $2.17 | +0.06% |
| Jul 19 | $1.87 | $2.02 | $2.18 | +0.07% |
| Jul 20 | $1.86 | $2.02 | $2.20 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.86 | $2.02 | $2.20 | +0.08% |
| Week 2 | $1.80 | $2.02 | $2.28 | +0.16% |
| Week 3 | $1.75 | $2.02 | $2.34 | +0.24% |
| Week 4 | $1.71 | $2.03 | $2.40 | +0.32% |
| Week 5 | $1.68 | $2.03 | $2.45 | +0.40% |
| Week 6 | $1.65 | $2.03 | $2.49 | +0.47% |
| Week 7 | $1.63 | $2.03 | $2.53 | +0.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Daré Bioscience, Inc. is a healthcare company focused on developing therapies in contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.
Its portfolio includes XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis, and Ovaprene, a hormone-free monthly intravaginal contraceptive, along with Sildenafil Cream for topical administration to the female genitalia for the treatment of female sexual arousal disorder, DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy, DARE-VVA1 for the treatment of dyspareunia, and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital HPV infection and related pathologies. The company also develops DARE-PDM1, a diclofenac hydrogel for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable etonogestrel formulations for contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring to deliver bio-identical progesterone for luteal phase support in in vitro fertilization; and DARE-PTB2 for prevention of preterm birth, among others such as DARE-LARC1, DARE-RH1, and DARE-GML.
Daré Bioscience was founded in 2015 and is headquartered in San Diego, California.
Daré Bioscience, Inc. (DARE) is a healthcare stock with a current price of $2.03. Its market capitalization is $30.41M and its market rank is 4725.
The forecast paints a path from near-term stability to longer-term growth, with 2026 average price $2.03, rising to 2030 average $2.75, 2040 average $4.27, and 2050 average $9.67. The max forecasts reach $4.65 in 2030, $8.98 in 2040, and $22.23 in 2050, with corresponding ROI values of 35.6, 110.4, and 376.1 respectively.
Near term, the model projects fluctuations with 2027 average $1.94 and 2028 average $1.72 before resuming a bullish trajectory toward 2030 and beyond.
A major floor 35.6% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
The nearest ceiling, 12.9% above — a clean break opens room to run.
A major ceiling 61.9% above — clearing it would confirm fresh momentum.
Key DARE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DARE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.05 | Sell | $2.05 | Sell |
| MA 10 | $2.07 | Sell | $2.06 | Sell |
| MA 20 | $2.07 | Sell | $2.08 | Sell |
| MA 50 | $2.26 | Sell | $2.12 | Sell |
| MA 100 | $2.01 | Buy | $2.09 | Sell |
| MA 200 | $1.99 | Buy | $2.14 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.53 | Neutral |
| Stoch RSI (14) | 8.49 | Buy |
| CCI (20) | -88.01 | Neutral |
| Williams %R (14) | -81.82 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -2.42 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 18.18 | Buy |
| TRIX (15) | -0.30 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 29.75 | Buy |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 2.03 | Sell |
| ADX (14) | 8.40 | Neutral |
| ATR (14) | 0.06 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 40.
The stock trades near the SMA50 of $2.27 and above the SMA200 of $1.99, with a near-term support at $1.85 and resistance at $3.27.
The 30-day trading range spans from $1.47 to $2.79.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.30 | $2.02 | $2.68 | 0% | Neutral | |
| $1.63 | $2.08 | $2.82 | +3% | Neutral | |
| $1.64 | $2.16 | $3.06 | +7% | Neutral | |
| $1.86 | $2.52 | $3.68 | +25% | Bullish | |
| $2.20 | $3.05 | $4.58 | +51% | Bullish | |
| $2.47 | $3.51 | $5.39 | +74% | Bullish | |
| $2.38 | $3.44 | $5.40 | +70% | Bullish | |
| $2.38 | $3.52 | $5.63 | +74% | Bullish | |
| $2.57 | $3.87 | $6.31 | +92% | Bullish | |
| $2.38 | $3.64 | $6.03 | +80% | Bullish | |
| $3.45 | $5.73 | $10.17 | +184% | Bullish | |
| $6.42 | $12.32 | $24.13 | +510% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.30 | $2.02 | $2.45 | +0.00% |
| August 2026 | $1.70 | $2.02 | $2.46 | -0.11% |
| September 2026 | $1.71 | $2.04 | $2.52 | +1.15% |
| October 2026 | $1.79 | $2.15 | $2.69 | +5.35% |
| November 2026 | $1.79 | $2.17 | $2.74 | +0.99% |
| December 2026 | $1.74 | $2.11 | $2.68 | -2.72% |
Click any year to see its month-by-month DARE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Daré Bioscience, Inc.'s 2026 outlook centres on $2.02, within a $1.30 to $2.68 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, DARE could reach as high as $2.82, with a base case around $2.08 and support toward $1.63 — roughly +3% from $2.02. Price action looks broadly range-bound.
Expect DARE to range from $1.64 to $3.06 through 2028. The $2.16 average target implies a +7% move from current prices. That is up +4% on the projected 2027 average. A consolidation phase looks the most probable path here.
The DARE price prediction for 2029 points to an average of $2.52 (low $1.86, high $3.68) — a potential gain of +25% on today's $2.02. Momentum favours further upside here.
In 2030, DARE is projected to trade between $2.20 and $4.58, averaging $3.05 — a potential gain of +51% from today's $2.02. That is up +21% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Daré Bioscience, Inc.'s 2031 outlook centres on $3.51, within a $2.47 to $5.39 range. That is up +15% on the projected 2030 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2032, DARE could reach as high as $5.40, with a base case around $3.44 and support toward $2.38 — roughly +70% from $2.02. Buyers look set to stay in control over this stretch.
Expect DARE to range from $2.38 to $5.63 through 2033. The $3.52 average target implies a +74% move from current prices. That is up +2% on the projected 2032 average. Momentum favours further upside here.
The DARE price prediction for 2034 points to an average of $3.87 (low $2.57, high $6.31) — a potential gain of +92% on today's $2.02. Buyers look set to stay in control over this stretch.
In 2035, DARE is projected to trade between $2.38 and $6.03, averaging $3.64 — a potential gain of +80% from today's $2.02. That is -6% versus the projected 2034 average. Momentum favours further upside here.
Daré Bioscience, Inc.'s 2040 outlook centres on $5.73, within a $3.45 to $10.17 range. That is up +57% on the projected 2035 average. That marks a +184% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, DARE could reach as high as $24.13, with a base case around $12.32 and support toward $6.42 — roughly +510% from $2.02. Momentum favours further upside here.
Investing $1,000 in DARE today (≈ 495.049505 DARE) could be worth
$6,101.3
+$5,101.3 (+510%) by 2050 · US Dollar
Based on the average projected DARE price of $12.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DAREwould be worth at today's price.
$1,000 invested in DARE on Jul 10, 2025 (≈ 418.410023 DARE) would be worth
$845.19
-$154.81 (-15.5%) today · 0.85× · US Dollar
Based on a DARE entry price of $2.39 vs. today's $2.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.09 | $966.51 | -3.3% |
| 1 month ago | $2 | $1,010 | +1.0% |
| 3 months ago | $1.83 | $1,103.83 | +10.4% |
| 6 months ago | $1.94 | $1,041.24 | +4.1% |
| 1 year ago | $2.39 | $845.19 | -15.5% |
| All time (5.0y) ago | $18.36 | $110.02 | -89.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DARE forecast.
Our base-case forecast reaches $4.00 around 2040.
Implied market cap at $4.00: $59.92M
The multi-year forecast shows a bullish tilt beginning into the 2030s, with 2030 average price of $2.75 and a max of $4.65, followed by continued gains through 2031–2035 (averages around the low to mid $3s with higher highs). The 2040 forecast projects an average of $4.27 with a max of $8.98 and a sustained bullish stance. By 2050, the average is $9.67 with a max of $22.23, supported by a bullish sentiment in that horizon and a long-run ROI of 35.6 in 2030, 110.4 in 2040, and 376.1 in 2050.
These are estimates, not guarantees, and reflect potential trajectories under the provided scenario. Risks include market movements, regulatory developments, and the success or failure of the company’s varied therapeutic programs.
Tap a question to reveal the answer.
2030 avg $2.75, min $1.76, max $4.65, ROI 35.6, sentiment BULLISH.
Forecasts show a long-term bullish trajectory with 2030 avg $2.75, 2040 avg $4.27, 2050 avg $9.67 and a 2050 max of $22.23, with ROI values of 35.6, 110.4, and 376.1 respectively.
The 2050 max forecast is $22.23 and the 2050 average is $9.67, indicating potential to exceed $10 in the long term, though these are not guarantees.
Current price $2.03; market cap $30.41M.
RSI14 40; SMA50 $2.27; SMA200 $1.99; support $1.85; resistance $3.27; 30-day range $1.47-$2.79.
Daré Bioscience, Inc. Community Discussion
0Share your Daré Bioscience, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.